EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fusion Pharmaceuticals's enterprise value is $1,637.08 Mil.
Fusion Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2.07 Mil. Therefore, Fusion Pharmaceuticals's EV-to-Revenue for today is 791.62.
The historical rank and industry rank for Fusion Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
FUSN'
s EV-to-Revenue Range Over the Past 10 Years
Min: -43.29 Med: 73.72 Max: 670.38
Current: 791.62
During the past 7 years, the highest EV-to-Revenue of Fusion Pharmaceuticals was 670.38. The lowest was -43.29. And the median was 73.72.
FUSN's EV-to-Revenue is ranked worse than 94.21% of 1036
companies
in the Biotechnology industry
Industry Median: 7.98
vs FUSN: 791.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fusion Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Fusion Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fusion Pharmaceuticals's EV-to-Revenue falls into.
Fusion Pharmaceuticals's current Enterprise Value is $1,637.08 Mil.
Fusion Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Pharmaceuticals's share price for today is $21.45.
Fusion Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Fusion Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FUSN has been successfully added to your 